Regenxbio drops after FDA rejects gene therapy for rare disease

Regenxbio

10/02/2026 09:49

** Shares of drug developer Regenxbio RGNX.O tumble 14% to $8.85 premarket

** U.S. Food and Drug Administration declines to approve co's gene therapy for a rare disease called Hunter syndrome, citing uncertainty regarding the trial design

** Co plans to seek meeting with the FDA on resubmitting its marketing application to provide further evidence on the patient population and additional longer-term clinical data

** Stock is about 36% below its 52-week intraday high of $16.19 reached on Jan 22, 2026

** Average rating of 13 analysts on the stock is 'buy' and their median price target is $29 - as per LSEG-compiled data

** RGNX stock has sunk ~28% YTD vs a 6.8% rise in the S&P 500 Biotechnology .SPLRCTKBI index

(Reporting by Joel Jose in Bengaluru)

((mail to: Joeljose@thomsonreuters.com))